Source comparison
PT-141 for Low Libido: Efficacy Comparison
PT-141 (Bremelanotide) Melanocortin receptor agonist (CNS) 30–60 minutes 6–12 hours Low libido, hypoactive sexual desire disorder 72% (vs 38% placebo) Nausea (40%), flushing (20%), transient BP increase Sildenafil (Viagra) PDE5 inhibitor (peripheral vascular)
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- Melanocortin receptor agonist (CNS)
- 30–60 minutes
- 6–12 hours
- Low libido, hypoactive sexual desire disorder
- 72% (vs 38% placebo)
- Nausea (40%), flushing (20%), transient BP increase
- Sildenafil (Viagra)
- PDE5 inhibitor (peripheral vascular)
- 4–6 hours
- Erectile dysfunction, inadequate genital blood flow
- 70–85% (erectile function restoration)
- Headache (16%), flushing (10%), vision disturbances (3%)
- Flibanserin (Addyi)
- Serotonin receptor modulator (CNS)
- 8+ weeks daily dosing
- Chronic (daily use required)
- Premenopausal HSDD
- 46% (vs 36% placebo)
- Dizziness (11%), somnolence (11%), contraindicated with alcohol
- Testosterone Replacement
- Androgen receptor activation
- 2–4 weeks (for libido effects)
- Continuous (weekly or daily dosing)
- Hypogonadism, age-related low libido
- 60–80% (libido improvement with normalised testosterone)
- Acne, hair loss, cardiovascular risk in high doses
- PT-141's advantage is that it works acutely and on-demand without requiring daily dosing or chronic receptor modulation. Flibanserin requires 8+ weeks of daily administration before libido effects manifest, and discontinuation leads to rapid loss of benefit. Testosterone replacement is effective for individuals with clinically low testosterone but carries androgenic side effects and is less effective when baseline testosterone is normal. PT-141 targets arousal circuitry independently of baseline hormone levels, making it effective even when testosterone, oestrogen, and other sex hormones are within normal physiological ranges.